Diffusion‐weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer

• Published in: Journal of magnetic resonance imaging Vol. 50; no. 3; pp. 836 - 846
• Main Authors: Horvat, Joao V., Bernard‐Davila, Blanca, Helbich, Thomas H., Zhang, Michelle, Morris, Elizabeth A., Thakur, Sunitha B., Ochoa‐Albiztegui, R. Elena, Leithner, Doris, Marino, Maria A., Baltzer, Pascal A., Clauser, Paola, Kapetas, Panagiotis, Bago‐Horvath, Zsuzsanna, Pinker, Katja
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.09.2019; Wiley Subscription Services, Inc
• Subjects: apparent diffusion coefficient: magnetic resonance imaging; Biomarkers; Breast cancer; Correlation coefficient; Correlation coefficients; Diagnostic systems; Diffusion coefficient; Diffusion rate; diffusion weighted imaging; Estrogen receptors; Estrogens; Field strength; Histograms; Histopathology; Image processing; immunohistochemistry; Invasiveness; Magnetic resonance imaging; Mapping; Medical imaging; molecular subtypes; Normality; Original Research; Progesterone; Readers; Statistical analysis; Statistical tests; Tumors; molecular subtypes; breast cancer; diffusion weighted imaging; immunohistochemistry; apparent diffusion coefficient: magnetic resonance imaging
• ISSN: 1053-1807; 1522-2586; 1522-2586
• DOI: 10.1002/jmri.26697

Background Diffusion‐weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping is one of the most useful additional MRI parameters to improve diagnostic accuracy and is now often used in a multiparameric imaging setting for breast tumor detection and characterization. Purpose To evaluate whether different ADC metrics can also be used for prediction of receptor status, proliferation rate, and molecular subtype in invasive breast cancer. Study Type Retrospective. Subjects In all, 107 patients with invasive breast cancer met the inclusion criteria (mean age 57 years, range 32–87) and underwent multiparametric breast MRI. Field Strength/Sequence 3 T, readout‐segmented echo planar imaging (rsEPI) with IR fat suppression, dynamic contrast‐enhanced (DCE) T1‐weighted imaging, T2‐weighted turbo‐spin echo (TSE) with fatsat. Assessment Two readers independently drew a region of interest on ADC maps on the whole tumor (WTu), and on its darkest part (DpTu). Minimum, mean, and maximum ADC values of both WTu and DpTu were compared for receptor status, proliferation rate, and molecular subtypes. Statistical Tests Wilcoxon rank sum, Mann–Whitney U‐tests for associations between radiologic features and histopathology; histogram and q‐q plots, Shapiro–Wilk's test to assess normality, concordance correlation coefficient for precision and accuracy; receiver operating characteristics curve analysis. Results Estrogen receptor (ER) and progesterone receptor (PR) status had significantly different ADC values for both readers. Maximum WTu (P = 0.0004 and 0.0005) and mean WTu (P = 0.0101 and 0.0136) were significantly lower for ER‐positive tumors, while PR‐positive tumors had significantly lower maximum WTu values (P = 0.0089 and 0.0047). Maximum WTu ADC was the only metric that was significantly different for molecular subtypes for both readers (P = 0.0100 and 0.0132) and enabled differentiation of luminal tumors from nonluminal (P = 0.0068 and 0.0069) with an area under the curve of 0.685 for both readers. Data Conclusion Maximum WTu ADC values may be used to differentiate luminal from other molecular subtypes of breast cancer. Level of Evidence: 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;50:836–846.